Alzheimer’s Trial to Test Drug on People Without Symptoms to See if Alzheimer’s Can Be Prevented

Alzheimer’s Trial to Test Drug on People Without Symptoms to See if Alzheimer’s Can Be Prevented

Researchers worldwide are conducting clinical trials to determine whether early treatment with experimental drugs can delay or prevent dementia—especially Alzheimer’s disease—before symptoms appear.

To do this, the investigators are recruiting participants who do not have dementia but have a genetic predisposition for developing the disorder. The trials involve drugs that target amyloid plaques, toxic protein deposits that accumulate in the brain and eventually kill brain cells. Amyloid plaques are a key feature associated with dementia.

Dementia is a broad term for a range of conditions that affect the brain. These conditions cause a decline in memory, thinking, problem-solving, and other cognitive skills. The conditions tend to worsen over time and interfere with daily life. Alzheimer’s disease is the most common form of dementia.

One international study has already shown positive results with anti-amyloid drugs. Investigators at the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU) found that early treatment using an anti-amyloid drug to remove amyloid plaques from the brain might slow cognitive decline if taken years before Alzheimer’s symptoms appear.

The DIAN-TU study, based at Washington University (WashU) School of Medicine in St. Louis, involved 73 participants in their 30s, 40s, or 50s with rare genetic mutations that cause excessive amyloid buildup in the brain. This almost guarantees they’ll develop Alzheimer’s in middle age.

For 22 participants who had no cognitive problems at the start of the study and received the anti-amyloid drug the longest (an average of eight years), the study’s data analyses show their risk of developing symptoms dropped from 100 percent to about 50 percent.

“Everyone in this study was destined to develop Alzheimer’s disease, and some of them haven’t yet,” senior author Dr. Randall J. Bateman, the Charles F. and Joanne Knight Distinguished Professor of Neurology at WashU Medicine, said in a news release. “We don’t yet know how long they will remain symptom-free—maybe a few years or maybe decades.”

What they do know, Dr. Bateman continued, is that “it’s possible at least to delay the onset of the symptoms of Alzheimer’s disease and give people more years of healthy life.”

This group continued to receive treatment with another anti-amyloid drug in hopes that they will remain “cognitively normal,” Dr. Bateman said.

Study Aims To Get Ahead of Alzheimer’s

An international study is underway in about 100 locations in North America, Asia, and Europe to see if the drug lecanemab (Lequembi) can help patients get ahead of Alzheimer’s disease symptoms.

Lecanemab has already been approved by the U.S. Food and Drug Administration and other regulatory agencies around the globe for those who already have mild cognitive impairment or mild dementia from Alzheimer’s.

The aim of the AHEAD study is to determine whether starting treatment with lecanemab much earlier can clear the amyloid-beta protein plaques before brain damage causes Alzheimer’s symptoms.

The 55- to 80-year-old participants in the AHEAD study have no symptoms or memory problems, but they do have amyloid plaques in the brain and are at risk for developing Alzheimer’s dementia.

“Our hope is to change the trajectory of their future cognitive health for the better,” Dr. Arash Salardini, the clinical trial’s principal investigator at the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, said in a news release. The institute, which is part of The University of Texas Health Science Center at San Antonio, is one of several sites in the United States participating in the AHEAD study.
The four-year AHEAD study consists of two clinical trials. While participants in both trials are cognitively normal, one group has elevated levels of brain amyloid, and the other has intermediate levels.

Participants with elevated levels of brain amyloid will receive a lecanemab injection once every two weeks for two years and then once every four weeks for the remainder of the study. People with intermediate levels of brain amyloid will receive an injection once every four weeks for four years.

Dr. Joshua D. Grill, a professor of psychiatry and human behavior and neurobiology and behavior at the University of California, Irvine (UCI), gives study participants credit for helping researchers “answer the important questions that are being tackled by the AHEAD study.” UCI is also a study site in the United States.

“The people who participate in these studies are my absolute heroes,” Dr. Grill, who is involved in the study, said in an episode of the BrightFocus Foundation’s Zoom In on Dementia and Alzheimer’s webinar.
“They are certainly hoping to benefit, but they are driven by helping scientists and doctors make progress in something that they know to be an extremely important topic.”

New Drug in the UK Fights Amyloid Plaques

Efforts to tackle Alzheimer’s dementia are continuing in the United Kingdom (UK), where a major study will determine whether a new drug could help prevent Alzheimer’s in people who do not yet have symptoms.

Trontinemab, developed by the Swiss-based Roche pharmaceutical company, is at the center of the global phase 3 PrevenTron clinical trial, which the company is also sponsoring. Trontinemab is an antibody treatment that targets amyloid plaques in the brain.

Early trials have raised researchers’ hopes after studies showed that trontinemab removes amyloid plaques faster than lecanemab and donanemab, the only two anti-amyloid drugs approved for marketing. At high doses, patients’ brains were free of amyloid after just three monthly infusions of trontinemab.

After enrolling participants in phase 3 of the PrevenTron trial, researchers will test them to ensure they do not have memory problems before giving them a blood test for p-tau217, a biomarker that can predict cognitive decline and the development of Alzheimer’s disease.

Earlier studies found that people with the highest p-tau217 levels had an estimated 78 percent chance of developing cognitive problems within 10 years. Research has also shown that blood tests for p-tau217 can detect Alzheimer’s disease with up to 95 percent accuracy.

Trontinemab is considered a “game changer” after early research showed that it cleared amyloid plaques in nine out of 10 people with early-stage Alzheimer’s or mild cognitive problems within 28 weeks. This means one of the primary characteristics of Alzheimer’s was removed.

The PrevenTRON trial shows researchers are shifting their attention from finding a cure to preventing it, according to Ramin Nilforooshan, the trial’s main investigator and a professor in psychiatry at the University of Surrey (UK).

“For decades, research has focused on treating Alzheimer’s disease after symptoms appear,” Nilforooshan told The Daily Telegraph. “PrevenTRON addresses a different question, whether we can act earlier, before symptoms begin.”

At least 15 hospitals and clinics across the UK are expected to participate by the end of the year. The trial is expected to last four to six years.

While research and trials can help millions of people avoid developing Alzheimer’s, Nilforooshan stressed that the treatment is only experimental.
“I’m not saying this trial is magic. It’s an investigational medicine. We need to wait and see: will it work or not?” Nilforooshan said.

Source Links:

https://medicine.washu.edu/news/anti-amyloid-drug-shows-signs-of-preventing-alzheimers-dementia/
https://www.brightfocus.org/resource/the-ahead-study-can-alzheimers-be-prevented-or-slowed-before-symptoms-begin/
https://www.theguardian.com/society/2026/sep/05/alzheimers-trial-drug-dementia?CMP=oth_b-aplnews_d-1
https://news.uthscsa.edu/can-alzheimers-disease-be-delayed-or-stopped-before-the-symptoms-begin-a-new-clinical-trial-strives-to-find-answers-2/

Follow Us or Share this page: